Mohebbi N, Talebi A, Moghadamnia M, Nazari Taloki Z, Shakiba A
Basic Clin Neurosci. 2020; 11(2):185-200.
PMID: 32855778
PMC: 7368108.
DOI: 10.32598/bcn.11.covid19.2500.1.
Beumer J, Pillai V, Parise R, Christner S, Kiesel B, Rudek M
Br J Clin Pharmacol. 2015; 80(5):1097-108.
PMID: 26178713
PMC: 4631182.
DOI: 10.1111/bcp.12723.
Kharasch E, Stubbert K
Drug Metab Dispos. 2013; 41(12):2166-74.
PMID: 24067429
PMC: 3834136.
DOI: 10.1124/dmd.113.053991.
Lin H, DAgostino J, Kenaan C, Calinski D, Hollenberg P
Drug Metab Dispos. 2013; 41(10):1813-24.
PMID: 23886699
PMC: 3781371.
DOI: 10.1124/dmd.113.053108.
Gleason L, Luque A, Shah K
Clin Interv Aging. 2013; 8:749-63.
PMID: 23818773
PMC: 3693722.
DOI: 10.2147/CIA.S37738.
Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.
Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas D
Antimicrob Agents Chemother. 2013; 57(5):2154-60.
PMID: 23459477
PMC: 3632909.
DOI: 10.1128/AAC.02294-12.
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
Rudek M, Flexner C, Ambinder R
Lancet Oncol. 2011; 12(9):905-12.
PMID: 21570912
PMC: 3343721.
DOI: 10.1016/S1470-2045(11)70056-0.
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Kharasch E, Bedynek P, Walker A, Whittington D, Hoffer C
Clin Pharmacol Ther. 2009; 84(4):506-12.
PMID: 19238656
PMC: 3583338.
DOI: 10.1038/clpt.2008.102.
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.
Kharasch E, Bedynek P, Park S, Whittington D, Walker A, Hoffer C
Clin Pharmacol Ther. 2009; 84(4):497-505.
PMID: 19238655
PMC: 3583342.
DOI: 10.1038/clpt.2008.104.
Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.
Kharasch E, Hoffer C, Whittington D, Walker A, Bedynek P
Anesthesiology. 2009; 110(3):660-72.
PMID: 19225389
PMC: 3111241.
DOI: 10.1097/ALN.0b013e3181986a9a.
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
Kharasch E, Mitchell D, Coles R, Blanco R
Antimicrob Agents Chemother. 2008; 52(5):1663-9.
PMID: 18285471
PMC: 2346649.
DOI: 10.1128/AAC.01600-07.
Drug interactions with antiretrovirals.
Catanzaro L, Slish J, DiCenzo R, Morse G
Curr HIV/AIDS Rep. 2005; 1(2):89-96.
PMID: 16091228
DOI: 10.1007/s11904-004-0013-z.
Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.
Prueksaritanont T, Richards K, Qiu Y, Strong-Basalyga K, Miller A, Li C
Pharm Res. 2005; 22(1):71-8.
PMID: 15771232
DOI: 10.1007/s11095-004-9011-5.
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Fellay J, Marzolini C, Decosterd L, Golay K, Baumann P, Buclin T
Eur J Clin Pharmacol. 2005; 60(12):865-73.
PMID: 15657782
DOI: 10.1007/s00228-004-0855-8.
Drug interactions between antiretroviral drugs and comedicated agents.
de Maat M, Ekhart G, Huitema A, Koks C, Mulder J, Beijnen J
Clin Pharmacokinet. 2003; 42(3):223-82.
PMID: 12603174
DOI: 10.2165/00003088-200342030-00002.
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap C, Buclin T, Baumann P
Clin Pharmacokinet. 2002; 41(14):1153-93.
PMID: 12405865
DOI: 10.2165/00003088-200241140-00003.
Comorbid medical illness in psychiatric patients.
Goldman L
Curr Psychiatry Rep. 2000; 2(3):256-63.
PMID: 11122965
DOI: 10.1007/s11920-996-0019-x.
Drug Interactions with Antiretrovirals.
Morse
Curr Infect Dis Rep. 2000; 2(3):257-266.
PMID: 11095864
DOI: 10.1007/s11908-000-0043-7.
